Du är här

2016-02-04

Oasmia Pharmaceutical to Present at Upcoming Source Capital Group's 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New York

Oasmia Pharmaceutical AB
Company Announcement

Oasmia Pharmaceutical to Present at Upcoming Source Capital Group's 2016
Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in
New York

New York, 2016-02-04 08:30 CET (GLOBE NEWSWIRE) --

New York, February 4, 2016 -- Oasmia Pharmaceutical AB (OASM), a developer of a
new generation of drugs within human and veterinary oncology, today announced
that the company has been invited to present at Source Capital Group's 2016
Disruptive Growth & Healthcare Conference and the BIO CEO & Investor
Conference. Both events will be held in New York City during the second week
of February.

Conference Details are as Follows:

Conference: BIO CEO & Investor Conference
Date: Tuesday, Feb. 9, 2016
Time: 1:30 p.m. EST
Location: The Waldorf Astoria New York

Conference: Source Capital Group's 2016 Disruptive Growth & Healthcare
Conference
Date: Wednesday, Feb. 10, 2016
Time: 4:30 p.m. EST
Location: Convene Conference Center at 730 Third Avenue in New York City

During the presentations, Mr. Julian Aleksov, Executive Chairman of Oasmia will
provide an update on Oasmia’s new generations of drugs in the field of human
and veterinary oncology.

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of
human and veterinary oncology. The company’s product development aims to create
and manufacture novel nanoparticle formulations and drug-delivery systems based
on well-established cytostatics which, in comparison with current alternatives,
show improved properties, reduced side-effects, and expanded applications. The
company’s product development is based on its proprietary in-house research and
company patents. Oasmia is listed on NASDAQ USA (OASM.US), Frankfurt Stock
Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

For media relations:
Eric Fischgrund
Founder FischTank
Tel: +1 (646) 699 1414
E-mail: eric@fischtankpr.com

For investor relations:
Robert Haag
Managing Partner
IRTH Communications
Tel: +1 (866) 976 4784
E-mail: oasm@irthcommunications.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.